Pharmaceutical stocks decline 10% within 3 months of bill passage

Passage of the drug pricing bill imposes stricter Medicare price negotiation and out-of-pocket caps, reducing profitability for major pharma firms. Investors react by selling shares in anticipation of lower margins.

Implied probability (Yes)

70%